Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

FDA Grants Fast Track Status to Cancer Vaccine UV1 for Advanced Malignant Melanoma

October 25th 2021

The FDA has granted a fast track designation to the universal cancer vaccine UV1 for use in combination with checkpoint inhibitors in patients with unresectable or metastatic melanoma, either as an add-on therapy to pembrolizumab or to ipilimumab.

ctDNA Reduction Is Potentially Predictive of OS Vs RECIST in Metastatic Uveal Melanoma

October 4th 2021

A linear correlation between magnitude of circulating tumor DNA reduction and improved overall survival was observed in patients with metastatic uveal melanoma who were treated with tebentafusp, suggesting that ctDNA may be a better surrogate end point for OS compared with RECIST response criteria.

Relatlimab/Nivolumab Application for Frontline Advanced Melanoma Validated by EMA

October 1st 2021

The European Medicines Agency has validated its marketing authorization application for the fixed-dose combination of relatlimab and nivolumab in the frontline treatment of adult and pediatric patients with advanced melanoma.

Dr. Hamid on the Integration of TIL-Based Therapy Into Melanoma

September 30th 2021

Omid Hamid, MD, discusses the integration of tumor infiltrating lymphocyte–based therapy into the melanoma armamentarium.

Relatlimab/Nivolumab Improves PFS Without Added Toxicity in Metastatic Melanoma, Underscoring Frontline SOC Potential

September 30th 2021

Hussein A. Tawbi, MD, PhD, discusses the safety and efficacy achieved with relatlimab plus nivolumab in the RELATIVITY-047 trial and sheds light on the clinical significance of the data in the melanoma treatment paradigm.

FDA Grants Priority Review to Relatlimab/Nivolumab for Unresectable or Metastatic Melanoma

September 20th 2021

The FDA has granted priority review to a biologics license application for the fixed-dose combination of relatlimab plus nivolumab for the treatment of adult and pediatric patients aged 12 years and older and weighing at least 40 kg who have unresectable or metastatic melanoma.

Dr. Luke on the Results of the Phase 3 KEYNOTE-716 Trial in Melanoma

September 19th 2021

Jason J. Luke, MD, FACP, discusses the results of the phase 3 KEYNOTE-716 trial in high-risk stage II melanoma.

ctDNA a Viable Surrogate for OS in Previously Treated Metastatic Uveal Melanoma

September 19th 2021

Circulating tumor DNA was a better predictor for survival than RECIST 1.1 for patients with previously treated, HLA-A*02:01-positive metastatic uveal melanoma assigned to tebentafusp.

Adjuvant Pembrolizumab Induces RFS Benefit in Resected High-Risk Stage II Melanoma

September 18th 2021

Adjuvant pembrolizumab led to a significant reduction in the risk of disease recurrence or death compared with placebo in patients with resected, high-risk stage II melanoma.

Dr. Janku on the Efficacy of Ripretinib in KIT-Mutated Melanoma

September 17th 2021

Filip Janku, MD, PhD, discusses the results form a phase 1 study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma.

The Hamilton of Medicine

September 3rd 2021

Most physician-scientists are intense, motivated and focused, but Keith T. Flaherty, MD, takes it to another level.

UV1 Vaccine Plus Pembrolizumab Shows Strong Safety, Early Activity in Metastatic Melanoma

September 2nd 2021

The universal cancer vaccine UV1 and granulocyte-macrophage colony-stimulating factor in combination with pembrolizumab elicited encouraging initial signs of clinical response with favorable safety and tolerability when used in the first-line treatment of patients with metastatic melanoma, meeting the primary end point of an ongoing phase 1 trial.

Topical Remetinostat Demonstrates Efficacy, Tolerability in Basal Cell Carcinoma

September 1st 2021

The topical HDAC inhibitor remetinostat demonstrated favorable tolerability and clinically significant efficacy in reducing disease burden in patients with basal cell carcinoma, according to results from a phase 2 trial.

Prior Treatment Confers Reduced Responses With Adoptive Transfer of TIL Therapy in Metastatic Melanoma

August 26th 2021

Prior treatment with PD-1 or MAPK inhibitors resulted in lower objective response rates with adoptive cell transfer of autologous tumor-infiltrating lymphocytes in patients with metastatic melanoma vs patients who were naïve to these agents.

FDA and EMA Accept Tebentafusp Applications for Metastatic Uveal Melanoma

August 24th 2021

The FDA and the European Medicines Agency have accepted applications seeking the approval of tebentafusp for use in the treatment of adult patients with HLA-A*02:01–positive metastatic uveal melanoma.

Clinicopathologic and Genomic Testing Confirm Differences in Pediatric Melanocytic Tumors

August 24th 2021

Distinct subgroups of pediatric melanocytic lesions, which were identified by an integrated clinicopathologic and genomic analysis, were found to have different clinical behaviors, suggesting that this combined diagnostic modality could inform individualized diagnoses and treatments for patients with these rare malignancies.

Dr. Funchain on the Rationale for the SWOG S1404 Trial in Melanoma

August 20th 2021

Pauline Funchain, MD, discusses the rationale for the phase 3 SWOG S1404 trial in high-risk resected melanoma.

Research Reflections: Weber Relays Melanoma Updates From the 2021 ASCO Annual Meeting

August 5th 2021

Dr. Weber discusses exciting research presented during the 2021 ASCO Annual Meeting in melanoma with combination and single-agent checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and more.

FDA Grants Priority Review to Adjuvant Pembrolizumab for Stage II High-Risk Melanoma

August 5th 2021

The FDA has granted priority review to a supplemental biologics license application for pembrolizumab for the use as an adjuvant treatment in adult and pediatric patients with stage IIB or IIC melanoma following complete resection.

Future Management of Uveal Melanoma

August 2nd 2021

The next steps in research investigating best practices using novel therapies such as tebentafusp as treatment for uveal melanoma.